List of Excipients in Branded Drug GALAFOLD

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Amicus Therapeutics US LLC	GALAFOLD	migalastat hydrochloride	71904-100	FD&C BLUE NO. 2	2039-02-16
Amicus Therapeutics US LLC	GALAFOLD	migalastat hydrochloride	71904-100	FERROSOFERRIC OXIDE	2039-02-16
Amicus Therapeutics US LLC	GALAFOLD	migalastat hydrochloride	71904-100	GELATIN	2039-02-16
Amicus Therapeutics US LLC	GALAFOLD	migalastat hydrochloride	71904-100	MAGNESIUM STEARATE	2039-02-16
Amicus Therapeutics US LLC	GALAFOLD	migalastat hydrochloride	71904-100	POTASSIUM HYDROXIDE	2039-02-16

Galafold Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Galafold, the brand name for migalastat hydrochloride, is an oral small-molecule treatment for adults with Fabry disease who have an amenable mutation. Its excipient strategy is commercially conservative: a hard gelatin capsule, a small inactive-ingredient set, and no complex delivery technology. The strongest opportunities are therefore in supply security, equivalent generic formulation, regional manufacturing, pediatric dosage forms, and improved administration rather than in premium excipient substitution.

Galafold’s commercial value is concentrated in its active pharmaceutical ingredient, regulatory status, orphan-disease positioning, genotype-specific efficacy, and established distribution network. Excipients represent a small percentage of product cost but can influence bioequivalence, stability, capsule performance, manufacturing yield, and generic launch timing.

What excipients are used in Galafold capsules?

Galafold contains migalastat hydrochloride equivalent to 123 mg of migalastat in a 150 mg capsule strength. The United States product is supplied as a hard capsule taken every other day on an empty stomach. The FDA-approved inactive ingredients include pregelatinized starch, magnesium stearate, and colloidal silicon dioxide. The capsule shell contains gelatin, titanium dioxide, and FD&C Blue No. 2. [1]

Component	Function	Strategic relevance
Pregelatinized starch	Filler, binder, and disintegration aid	Supports compactability and capsule-fill consistency
Magnesium stearate	Lubricant	Controls powder ejection and manufacturing friction
Colloidal silicon dioxide	Glidant and moisture-flow aid	Improves powder flow and blend uniformity
Gelatin	Hard-capsule shell	Provides immediate-release dosage form
Titanium dioxide	Opacifier and colorant	Supports appearance and light protection
FD&C Blue No. 2	Capsule colorant	Supports product identification and branding

The formulation is a conventional immediate-release capsule. It does not depend on a polymeric controlled-release matrix, lipid formulation, enteric coating, biologic stabilizer, or device-based delivery system.

What is the formulation design of Galafold?

Galafold uses a low-complexity powder-filled capsule. The formulation must deliver consistent release after administration on an empty stomach while maintaining chemical and physical stability through the product shelf life.

The primary formulation controls are:

• Powder flow and capsule-fill uniformity.
• Lubricant concentration and mixing time.
• Moisture control for the starch-containing blend.
• Capsule-shell mechanical integrity.
• Disintegration and dissolution under immediate-release conditions.
• Compatibility between migalastat hydrochloride and the excipient blend.
• Control of impurities and degradation products.

Because migalastat is administered intermittently rather than multiple times each day, capsule strength and dose uniformity are commercially important. A failure in fill-weight control or dissolution can directly affect regulatory comparability.

How strong is the Galafold excipient strategy?

The excipient strategy is operationally robust but not highly differentiated. Its strengths are low formulation complexity, broad availability of most ingredients, and the absence of specialized delivery equipment. Its limitations are limited product differentiation and a relatively straightforward path for conventional generic formulation development.

Strengths

1. The formulation uses commonly available pharmaceutical excipients.
2. The immediate-release capsule format is familiar to generic manufacturers.
3. The product does not require a proprietary delivery device.
4. Excipient substitutions can potentially be evaluated through standard pharmaceutical development and bioequivalence programs.
5. Capsule manufacturing can be transferred across qualified contract manufacturing organizations with fewer technical barriers than a modified-release or biologic product.

Constraints

The empty-stomach dosing requirement restricts certain formulation strategies. A reformulation that changes gastric dissolution, food sensitivity, or exposure could require substantial clinical and regulatory support. Excipients that accelerate dissolution may not be commercially advantageous if they alter pharmacokinetics.

The product also targets a rare disease. That limits the value of small improvements in manufacturing economics unless the reformulated product supports a major commercial objective, such as pediatric use, geographic expansion, reduced supply risk, or generic entry.

What commercial opportunities exist in Galafold excipients?

The main opportunities fall into five categories: equivalent generic development, alternate suppliers, pediatric dosage forms, improved capsule technology, and regional production.

Opportunity	Commercial rationale	Technical hurdle	Relative attractiveness
Equivalent hard capsule	Standard route for generic competition	Bioequivalence and CMC comparability	High
Alternate excipient sourcing	Reduces supply-chain concentration	Supplier qualification and change control	Medium
Pediatric mini-capsule	Addresses swallowing and dose flexibility	Dose accuracy and pediatric acceptability	Medium-high
Sprinkle or dispersible dosage form	Could improve administration for children	Food-effect and exposure studies	Medium
Capsule-shell reformulation	May reduce animal-origin or colorant concerns	Stability, appearance, and regulatory review	Low-medium
Modified-release formulation	Potential dosing convenience	Clinical development and uncertain benefit	Low
New salt or co-crystal	Could improve processability	New IP and extensive regulatory work	Low

Can excipient suppliers sell directly into the Galafold market?

Yes, but the opportunity is primarily supply-chain based rather than product-brand based. Suppliers of pregelatinized starch, magnesium stearate, colloidal silicon dioxide, and capsule shells can compete for qualified supply positions with Amicus Therapeutics, contract manufacturers, and future generic applicants.

The most attractive supply opportunities are:

• Dual-source qualification for critical excipients.
• Low-moisture grades of starch and colloidal silicon dioxide.
• Consistent particle-size distributions.
• Low-bioburden and high-microbial-control materials.
• Non-animal or vegetarian capsule shells.
• Global regulatory packages supporting United States, European Union, Japanese, and other markets.
• Supplier change packages designed for post-approval notification.

Excipient suppliers would gain more value from becoming qualified in a regulatory filing than from selling spot-market material. For an orphan product, annual volume may be modest, so the commercial case depends on long-term qualification, participation in generic supply, or use across multiple products.

What formulation patents protect Galafold?

The principal commercial protection for Galafold has historically come from the active ingredient, use of migalastat in Fabry disease, genotype-specific treatment concepts, and regulatory exclusivity. The capsule excipient combination is less likely to create a strong standalone barrier unless a patent claims a narrow formulation with unexpected stability, bioavailability, impurity control, or manufacturing advantages.

Protection category	Relevance to Galafold	Effect on excipient opportunity
Migalastat compound patents	Protect the active molecule or salt	Can delay conventional generic entry
Method-of-use patents	Cover treatment of Fabry disease or amenable mutations	May limit labeled generic commercialization
Formulation patents	May cover composition, stability, or release	Could constrain excipient substitution
Manufacturing patents	Cover synthesis, purification, or crystallization	May affect API sourcing more than capsule excipients
Orphan-drug exclusivity	Regulatory protection, not patent protection	Can block approval of the same orphan indication
Trademark protection	Protects Galafold branding	Does not prevent generic formulation

A generic company can often avoid a formulation claim by changing the excipient grade or concentration while preserving the required performance profile. That strategy depends on the wording of issued claims, the FDA Orange Book listing, ANDA certification, and the applicant’s bioequivalence data. [3]

No biosimilar pathway applies to Galafold because migalastat is a small-molecule drug, not a biologic. Competitive entrants would generally use an ANDA for an equivalent product or, in some cases, a 505(b)(2) application for a materially different dosage form or clinical use. [4]

When does Galafold lose exclusivity?

Galafold’s exclusivity timeline has several separate components. Patent expiration, orphan-drug exclusivity, pediatric exclusivity, and regulatory approval timing do not have identical end dates.

Milestone	United States relevance
FDA approval	August 2018
Orphan-drug exclusivity	Seven years from approval for the protected indication, subject to statutory exceptions
Patent protection	Depends on issued claims, terminal disclaimers, patent-term adjustment, and listed patents
Pediatric exclusivity	Adds six months only if granted after completion of an applicable written request
Generic pathway	ANDA filing may occur before patent expiration through Paragraph IV certification

The FDA approved Galafold in August 2018 for adults with Fabry disease and an amenable mutation. [1] The associated seven-year orphan-drug period therefore reached its ordinary statutory endpoint in 2025, unless a separate regulatory event affected the calculation. Orphan exclusivity does not prevent every possible competing product. It generally blocks approval of the same drug for the same disease or condition during the exclusivity period, subject to statutory exceptions.

Patent expiration dates must be determined from the current Orange Book and the underlying patent records. A patent term can differ from the nominal 20-year period because of patent-term adjustment, patent-term extension, terminal disclaimers, or patent-specific prosecution history. [3]

What is the Orange Book status of Galafold?

Galafold is an FDA-approved small-molecule prescription product and is evaluated through the Orange Book framework used for therapeutic-equivalence and patent-listing information. The relevant review should include:

• Listed patents for the reference product.
• Patent expiration dates.
• Any pediatric exclusivity notation.
• Product-specific reference standard status.
• Whether a listed patent covers the active ingredient, formulation, method of use, or another aspect of the product.
• Any FDA-approved labeling changes affecting the protected use.

The Orange Book is the controlling public source for listed patent information for an ANDA strategy. Patent databases alone are not sufficient because a patent may exist without being listed for the reference product, while a listed patent may cover only a particular approved use or formulation. [3]

Which companies are challenging Galafold?

Publicly visible competition is more likely to emerge from generic drug manufacturers after relevant regulatory and patent barriers expire than from biosimilar developers. No biosimilar competition is expected because Galafold is not a biologic.

A generic challenger would likely evaluate:

1. A conventional hard capsule matching the 123 mg migalastat-equivalent strength.
2. A Paragraph III certification if relevant listed patents remain unexpired.
3. A Paragraph IV certification alleging invalidity, unenforceability, or non-infringement.
4. An ANDA based on comparative dissolution and pharmacokinetic bioequivalence.
5. A 505(b)(2) route for a pediatric, dispersible, or otherwise differentiated product.

A Paragraph IV filing can trigger patent litigation under the Hatch-Waxman framework. The commercial outcome may include a 30-month stay of approval, an early settlement, a license date, or a court decision allowing earlier launch. [4]

What patent litigation and settlement risks affect Galafold?

The principal litigation risks are conventional for a branded small molecule:

• Challenges to compound or salt patents.
• Challenges to method-of-use claims for Fabry disease.
• Arguments that formulation claims are obvious or lack written description.
• Non-infringement positions based on altered excipient ratios or capsule-shell materials.
• Antitrust scrutiny if a settlement delays generic entry beyond a defensible patent position.

An excipient strategy can reduce formulation-patent exposure, but it does not eliminate compound or method-of-use risk. A generic company may also need to use a Section viii statement to carve out a patented indication from labeling rather than challenge the patent directly. That strategy becomes difficult where the principal commercial use is closely tied to the protected indication.

Publicly identified litigation, settlements, and launch dates should be checked against PACER, FDA approval records, and the current Orange Book before an investment or licensing decision. [3,5]

What manufacturing and geographic barriers exist?

Galafold is comparatively accessible from a manufacturing standpoint because it is an oral capsule. The more significant barriers are regulatory, commercial, and API-related.

United States

The United States market requires FDA-compliant API and finished-dose manufacturing, an ANDA or other approved pathway, and compliance with listed patents and exclusivity. Generic companies also need a reference standard and adequate comparative dissolution and pharmacokinetic data.

European Union

The European Union adds centralized regulatory requirements, national pricing and reimbursement decisions, and country-specific substitution practices. Orphan designation and market exclusivity can affect timing independently from United States protection. The European Medicines Agency describes Galafold as an oral treatment for adults with confirmed Fabry disease and an amenable mutation. [2]

Asia-Pacific and other markets

Markets such as Japan, South Korea, Australia, and selected emerging markets may present opportunities for local licensing, packaging, and supply partnerships. The value of an excipient or capsule change depends on whether the local regulator accepts a bridging approach or requires new clinical evidence.

Manufacturing barriers

The key manufacturing risks include:

• Reliable migalastat API supply.
• Control of polymorphic or solid-state properties.
• Moisture management.
• Consistent powder flow.
• Capsule-shell supply.
• Cross-market excipient compliance.
• Validation of alternative suppliers.
• Batch-size economics for a rare disease product.

The API is a more material barrier than the excipient blend. A low-cost excipient strategy does not produce a competitive product without dependable API access and regulatory clearance.

How does Galafold compare with agalsidase enzyme replacement therapy?

Galafold differs materially from Fabry enzyme replacement therapies such as agalsidase beta and agalsidase alfa.

Attribute	Galafold	Enzyme replacement therapy
Active ingredient	Small molecule	Recombinant enzyme
Administration	Oral capsule	Intravenous infusion
Excipient complexity	Low	Higher biologic formulation and container-control burden
Biosimilar pathway	Not applicable	Potentially relevant
Manufacturing barrier	Chemical API and capsule	Cell culture, purification, viral safety, and cold chain
Differentiation opportunity	Oral convenience, mutation amenability, pediatric delivery	Immunogenicity, infusion time, dose, and supply
Generic substitution	ANDA-type analysis	Biologic comparability and interchangeability issues

The simpler Galafold dosage form creates more opportunity for conventional generic competition but less room for premium excipient differentiation. Enzyme replacement products have higher formulation and manufacturing barriers, while Galafold has greater vulnerability to capsule-based substitution once regulatory and patent barriers fall.

What revenue exposure does the excipient strategy create?

Excipient costs are unlikely to drive Galafold revenue. The financial exposure is indirect:

• A capsule-shell shortage can interrupt supply despite low material cost.
• A supplier change can require regulatory reporting or approval.
• A formulation change can trigger new stability or bioequivalence work.
• A pediatric formulation can extend the product lifecycle.
• A generic capsule can reduce net pricing after exclusivity loss.
• A dual-source strategy can protect continuity but raise qualification costs.

Amicus reports Galafold product performance and company revenue in its public financial disclosures, but those reports do not generally isolate excipient costs or excipient-related margin effects. [6] The economic value of the excipient strategy is therefore best measured through avoided supply interruption, reduced manufacturing loss, regulatory flexibility, and lifecycle management.

What is the best commercial strategy for Galafold excipients?

The strongest strategy is to preserve the immediate-release capsule while improving supply resilience and preparing differentiated dosage forms only where a clear regulatory or market need exists.

Priority actions are:

1. Maintain at least two qualified suppliers for each critical excipient and capsule-shell component.
2. Control excipient particle size, moisture, microbial quality, and lubricant variability.
3. Develop a non-animal or vegetarian capsule option for selected markets.
4. Evaluate a pediatric mini-capsule or sprinkle presentation without changing exposure.
5. Map all formulation, method-of-use, and manufacturing patents before a generic filing.
6. Build global excipient documentation to support post-approval manufacturing changes.
7. Treat API availability and regulatory exclusivity as the primary commercial constraints.
8. Avoid modified-release or novel-delivery development unless clinical data show a material adherence or efficacy benefit.

Key Takeaways

• Galafold uses a conventional hard capsule with pregelatinized starch, magnesium stearate, colloidal silicon dioxide, gelatin, titanium dioxide, and FD&C Blue No. 2.
• Its excipient formulation is low complexity and technically reproducible.
• The principal commercial opportunities are generic hard capsules, alternate suppliers, pediatric formats, and supply-chain resilience.
• Galafold is a small molecule, so biosimilar competition does not apply.
• Generic entry depends on Orange Book patents, orphan-drug exclusivity, ANDA timing, and possible Paragraph IV litigation.
• API access and regulatory protection are more important barriers than the excipient blend.
• Modified-release and premium excipient strategies have limited commercial justification without demonstrated clinical value.
• A pediatric dosage form and dual-source manufacturing strategy offer the clearest lifecycle opportunities.

FAQs

Can a generic company use different excipients from Galafold?

Yes. A generic applicant may use different excipients if the formulation meets applicable quality, dissolution, stability, labeling, and bioequivalence requirements and does not infringe enforceable formulation claims.

Is Galafold eligible for a biosimilar application?

No. Migalastat is a chemically synthesized small molecule. A competing product would generally use an ANDA or, for a materially different product, a 505(b)(2) application.

Could a vegetarian capsule create a new Galafold product opportunity?

Yes, but the commercial value would depend on market demand, regulatory requirements, capsule-shell performance, stability, and whether the change supports pediatric, religious, dietary, or regional access objectives.

Would an orally disintegrating Galafold tablet have a strong commercial case?

Usually not without evidence of improved adherence, pediatric usability, food-condition flexibility, or pharmacokinetic performance. A new dosage form would face additional development and regulatory requirements.

Are Galafold excipients likely to block generic entry?

Usually no. Generic entry is more likely to be constrained by active-ingredient patents, method-of-use claims, regulatory exclusivity, API supply, and litigation than by the conventional excipient combination.

References

1. U.S. Food and Drug Administration. (2018). Galafold (migalastat hydrochloride) capsules: Prescribing information. https://www.accessdata.fda.gov
2. European Medicines Agency. (2016). Galafold: EPAR product information. https://www.ema.europa.eu
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
4. U.S. Food and Drug Administration. (2017). ANDAs for certain highly purified synthetic peptides: Guidance for industry. https://www.fda.gov
5. U.S. Courts. (n.d.). PACER case locator. https://pacer.uscourts.gov
6. Amicus Therapeutics, Inc. (2024). Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission. https://www.sec.gov/edgar.shtml